Peter Ho

Dr. Ho is a physician-scientist who has spent his career in cancer drug discovery and development. He has been directly responsible for the first-time-in-human dosing of 19 anticancer agents and has overseen the development of over 60 hematology and oncology compounds in all phases of clinical trials. His work has contributed to eleven NCE or biologics approvals to date: Gleevec^®; Arranon^®; Tykerb^®; Promacta^®; Votrient^®; Synribo^®; Tafinlar^®; Mekinist^®; Sylvant^®; and Rydap^®, and Tazverik^®.

He received his BA in biology from The Johns Hopkins University and his MD and PhD (pharmacology) degrees from Yale University, then completed a pediatrics residency at The Children’s Hospital of Boston followed by clinical fellowships in pediatric hematology/oncology at the Dana-Farber Cancer Institute and in clinical oncology and regulatory sciences jointly through the U.S. FDA and the NCI. He began his drug development work at the Investigational Drug Branch of the Cancer Therapy Evaluation Program, NCI followed by positions of increasing responsibility at Novartis and DuPont Pharmaceuticals. He subsequently served as Senior VP of the Oncology Center of Excellence in Drug Discovery at GlaxoSmithKline and VP of Oncology Clinical Development at Johnson and Johnson.

He moved from large pharma to biotech as co-Founder and President of BeiGene Ltd. based in Beijing, China. Most recently, he served as Chief Medical Officer at Epizyme Inc. and then at Boston Pharmaceuticals where he was responsible for and oversaw clinical development functional areas including medical, clinical operations, clinical pharmacology, regulatory affairs, translational medicine, biostatistics, and data management.

Dr. Ho is currently an Adjunct Associate Professor in the Division of Chemical Biology and Medicinal Chemistry at the Eshelman School of Pharmacy, University of North Carolina. He also currently serves on the Board of Directors of Aravive and Celeris Therapeutics, the Scientific Advisory Boards of Accent Therapeutics and Tavotek Biotherapeutics, the External Scientific Advisory Committee of the Cleveland Clinic’s Center for Therapeutics Discovery, in the Maryland Responds Medical Reserve Corps, and as a senior advisor to Overland Pharmaceuticals and D3 Bio. He previously served on the Pediatric Cancer Working Group of the Cancer Moonshot Task Force.